This study was aimed at obtaining conclusive evidence for the potential of liraglutide in mitigating diabetic cardiomyopathy via the modulation of the ILK/PI3K/Akt/PTEN signaling pathways. This evidence concerns the gene AKT1 and diabetic cardiomyopathy.